Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
8
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
deals
gene therapy
hemophilia
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
pfizer
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
celgene
clinical trials
fda
novartis
sangamo therapeutics
spark therapeutics
spinal muscular atrophy
bill cassidy
What
gene
8
×
therapy
bio
drug
roundup
fda
help
long
medicine
moves
past
patients
prices
race
advanced
age
alnylam
alnylam’s
alzheimer’s
approval
approves
aren’t
becker
bff
bigger
biggest
billions
cells
close
come
companies
conference
crude
cutting
data
deal
deals
despite
developers
devoted
Language
Current search:
gene
×
" new york top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More